CRCSEP Côte d'Azur, CHU de Nice Pasteur, Université Nice Côte d'Azur, Nice, France.
Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, 59 boulevard Pinel, F-69677 Bron, France; Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, F-69003 Lyon, France; Université de Lyon, Université Claude Bernard Lyon 1, F-69000 Lyon, France; Eugène Devic EDMUS Foundation against multiple sclerosis, F-69677 Bron, France.
Mult Scler Relat Disord. 2019 Jun;31:173-188. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10.
To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have been raised more recently about an increased risk of infection or a decreased effectiveness of immunization in immunosuppressed patients.
The French Group for Recommendations into Multiple Sclerosis (France4MS) performed a systematic search of papers in Medline and other university databases (January 1975-June 2018). The RAND/UCLA appropriateness method was chosen to review the scientific literature and to formalize the degree of agreement among experts on 5 clinical questions related to immunization and MS. Readers from the steering committee conducted a systematic analysis, wrote a critical synthesis and prepared a list of proposals that were evaluated by a rating group of 28 MS experts. The final version of the recommendations was finally reviewed by a reading group of 110 health care professionals and classified as appropriate, inappropriate or uncertain.
Neurologists should verify the vaccination status as soon as MS is diagnosed and before disease-modifying treatments (DMTs) are introduced. The French vaccination schedule applies to MS patients and seasonal influenza vaccination is recommended. In the case of treatment-induced immunosuppression, MS patients should be informed about the risk of infection and the vaccination standards of the French High Council of Health should be applied. Live attenuated vaccines are contra-indicated in patients recently treated with immunosuppressive drugs, including corticosteroids; other vaccines can be proposed whatever the treatment, but their effectiveness may be partly reduced with some drugs.
Physicians and patients should be aware of the updated recommendations for immunizations of patients with MS.
为多发性硬化症(MS)患者的免疫接种制定建议。
疫苗过去曾被怀疑引发 MS 和复发。随着免疫活性治疗手段的不断扩展,最近人们对免疫抑制患者感染风险增加或疫苗有效性降低提出了更多担忧。
法国多发性硬化症建议小组(France4MS)对 Medline 和其他大学数据库中的文献进行了系统搜索(1975 年 1 月至 2018 年 6 月)。选择 RAND/UCLA 适宜性方法来审查科学文献,并就 5 个与免疫接种和 MS 相关的临床问题正式确定专家之间的一致程度。来自指导委员会的读者进行了系统分析,撰写了批判性综述,并准备了一份提案清单,由 28 名 MS 专家组成的评分小组进行评估。最终版本的建议由 110 名医疗保健专业人员阅读小组进行审查,并归类为适当、不适当或不确定。
一旦确诊 MS 且在开始使用疾病修正治疗(DMT)之前,神经科医生应核实患者的疫苗接种情况。法国的疫苗接种计划适用于 MS 患者,建议接种季节性流感疫苗。在治疗引起的免疫抑制情况下,应告知 MS 患者感染风险,并应遵循法国健康高级理事会的疫苗接种标准。最近接受免疫抑制药物(包括皮质类固醇)治疗的患者禁用活减毒疫苗;无论治疗如何,都可以提出其他疫苗,但某些药物可能会部分降低其有效性。
医生和患者应了解 MS 患者免疫接种的最新建议。